BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis

NCT07151690 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Systemic Light Chain Amyloidosis

Interventions

DRUG: anti-BCMA/CD3 bispecific antibody

Sponsor

Institute of Hematology & Blood Diseases Hospital, China